
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
S
Cover
over 16 years ago
Applied Clinical Trials Digital Edition - June 2010over 16 years ago
Biosimilars Make Headwayover 16 years ago
Business and News Update June 2010over 16 years ago
Electronic Integration Costsover 16 years ago
Strategic Immunogenicity Testingover 16 years ago
ePRO vs. Paperover 16 years ago
Today's Global Site Landscapeover 16 years ago
Changing Medicines, Changing Rulesover 16 years ago
Ethics Diversity Persistsover 16 years ago
Mastering Currency Fluctuation





